APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Relapsed Acute Myeloid Leukemia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Relapsed Acute Myeloid Leukemia Drug Industry Growth and Trends Forecast to 2032

Report ID 174032120119 December 2025110 pages

Choose your research edition.

Industry ResearchRelapsed Acute Myeloid Leukemia Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Relapsed Acute Myeloid Leukemia Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Relapsed Acute Myeloid Leukemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Relapsed Acute Myeloid Leukemia Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Relapsed Acute Myeloid Leukemia Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Relapsed Acute Myeloid Leukemia Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Relapsed Acute Myeloid Leukemia Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Relapsed Acute Myeloid Leukemia Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Relapsed Acute Myeloid Leukemia Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Relapsed Acute Myeloid Leukemia Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Relapsed Acute Myeloid Leukemia Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Relapsed Acute Myeloid Leukemia Drug Market by Company

4SC AG

Amgen Inc.

AbbVie Inc.

AstraZeneca Plc

CTI BioPharma Corp.

Cornerstone Pharmaceuticals, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

Bristol-Myers Squibb Company

Boston Biomedical, Inc.

Boehringer Ingelheim GmbH

BioLineRx, Ltd.

AVEO Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc.

Astellas Pharma Inc.

Array BioPharma Inc.

Arog Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Relapsed Acute Myeloid Leukemia Drug Segment by Type

aNK Program

AT-9283

BI-836858

BL-8040

Binimetinib

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Application

Clinic

Hospital

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Relapsed Acute Myeloid Leukemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of aNK Program Table 2. Major Company of AT-9283 Table 3. Major Company of BI-836858 Table 4. Major Company of BL-8040 Table 5. Major Company of Binimetinib Table 6. Major Company of Others Table 7. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 9. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 14. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 19. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 21. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 25. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Relapsed Acute Myeloid Leukemia Drug Industry Trends Table 29. Relapsed Acute Myeloid Leukemia Drug Industry Drivers Table 30. Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges Table 31. Relapsed Acute Myeloid Leukemia Drug Industry Restraints Table 32. Global Relapsed Acute Myeloid Leukemia Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company (2021-2026) Table 34. Global Relapsed Acute Myeloid Leukemia Drug Sales by Company (2021-2026) & (K Units) Table 35. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Company (2021-2026) Table 36. Global Relapsed Acute Myeloid Leukemia Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Relapsed Acute Myeloid Leukemia Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Relapsed Acute Myeloid Leukemia Drug Major Company Production Sites and Headquarters Table 39. Global Relapsed Acute Myeloid Leukemia Drug Company, Product Type & Application Table 40. Global Relapsed Acute Myeloid Leukemia Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Relapsed Acute Myeloid Leukemia Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 61. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 66. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 68. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 72. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (US$ Million) Table 75. 4SC AG Company Information Table 76. 4SC AG Business Overview Table 77. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 79. 4SC AG Recent Development Table 80. Amgen Inc. Company Information Table 81. Amgen Inc. Business Overview Table 82. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 84. Amgen Inc. Recent Development Table 85. AbbVie Inc. Company Information Table 86. AbbVie Inc. Business Overview Table 87. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 89. AbbVie Inc. Recent Development Table 90. AstraZeneca Plc Company Information Table 91. AstraZeneca Plc Business Overview Table 92. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 94. AstraZeneca Plc Recent Development Table 95. CTI BioPharma Corp. Company Information Table 96. CTI BioPharma Corp. Business Overview Table 97. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 99. CTI BioPharma Corp. Recent Development Table 100. Cornerstone Pharmaceuticals, Inc. Company Information Table 101. Cornerstone Pharmaceuticals, Inc. Business Overview Table 102. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 104. Cornerstone Pharmaceuticals, Inc. Recent Development Table 105. Celgene Corporation Company Information Table 106. Celgene Corporation Business Overview Table 107. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 109. Celgene Corporation Recent Development Table 110. Calithera Biosciences, Inc. Company Information Table 111. Calithera Biosciences, Inc. Business Overview Table 112. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 114. Calithera Biosciences, Inc. Recent Development Table 115. Bristol-Myers Squibb Company Company Information Table 116. Bristol-Myers Squibb Company Business Overview Table 117. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 119. Bristol-Myers Squibb Company Recent Development Table 120. Boston Biomedical, Inc. Company Information Table 121. Boston Biomedical, Inc. Business Overview Table 122. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 124. Boston Biomedical, Inc. Recent Development Table 125. Boehringer Ingelheim GmbH Company Information Table 126. Boehringer Ingelheim GmbH Business Overview Table 127. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 129. Boehringer Ingelheim GmbH Recent Development Table 130. BioLineRx, Ltd. Company Information Table 131. BioLineRx, Ltd. Business Overview Table 132. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 134. BioLineRx, Ltd. Recent Development Table 135. AVEO Pharmaceuticals, Inc. Company Information Table 136. AVEO Pharmaceuticals, Inc. Business Overview Table 137. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 139. AVEO Pharmaceuticals, Inc. Recent Development Table 140. Astex Pharmaceuticals, Inc. Company Information Table 141. Astex Pharmaceuticals, Inc. Business Overview Table 142. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 144. Astex Pharmaceuticals, Inc. Recent Development Table 145. Astellas Pharma Inc. Company Information Table 146. Astellas Pharma Inc. Business Overview Table 147. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 149. Astellas Pharma Inc. Recent Development Table 150. Array BioPharma Inc. Company Information Table 151. Array BioPharma Inc. Business Overview Table 152. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 154. Array BioPharma Inc. Recent Development Table 155. Arog Pharmaceuticals, Inc. Company Information Table 156. Arog Pharmaceuticals, Inc. Business Overview Table 157. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 159. Arog Pharmaceuticals, Inc. Recent Development Table 160. Agios Pharmaceuticals, Inc. Company Information Table 161. Agios Pharmaceuticals, Inc. Business Overview Table 162. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 164. Agios Pharmaceuticals, Inc. Recent Development Table 165. Actinium Pharmaceuticals, Inc. Company Information Table 166. Actinium Pharmaceuticals, Inc. Business Overview Table 167. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 169. Actinium Pharmaceuticals, Inc. Recent Development Table 170. North America Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 171. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 172. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2026) Table 173. North America Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 174. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Country (2027-2032) Table 175. North America Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 177. North America Relapsed Acute Myeloid Leukemia Drug Market Share by Country (2021-2026) Table 178. North America Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. North America Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Country (2027-2032) Table 180. Europe Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 181. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 182. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2026) Table 183. Europe Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 184. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Country (2027-2032) Table 185. Europe Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 187. Europe Relapsed Acute Myeloid Leukemia Drug Market Share by Country (2021-2026) Table 188. Europe Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Europe Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Country (2027-2032) Table 190. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 191. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 192. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2026) Table 193. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 194. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Country (2027-2032) Table 195. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 197. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Share by Country (2021-2026) Table 198. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Country (2027-2032) Table 200. Latin America Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 201. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 202. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2026) Table 203. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 204. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Country (2027-2032) Table 205. Latin America Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 207. Latin America Relapsed Acute Myeloid Leukemia Drug Market Share by Country (2021-2026) Table 208. Latin America Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. Latin America Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Country (2027-2032) Table 210. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 211. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 212. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2026) Table 213. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 214. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Country (2027-2032) Table 215. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 216. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 217. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Share by Country (2021-2026) Table 218. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 219. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Country (2027-2032) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Relapsed Acute Myeloid Leukemia Drug Distributors List Table 223. Relapsed Acute Myeloid Leukemia Drug Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Relapsed Acute Myeloid Leukemia Drug Image Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Relapsed Acute Myeloid Leukemia Drug Sales (2021-2032) & (K Units) Figure 5. aNK Program Image Figure 6. Global aNK Program Sales YoY Growth (2021-2032) & (K Units) Figure 7. AT-9283 Image Figure 8. Global AT-9283 Sales YoY Growth (2021-2032) & (K Units) Figure 9. BI-836858 Image Figure 10. Global BI-836858 Sales YoY Growth (2021-2032) & (K Units) Figure 11. BL-8040 Image Figure 12. Global BL-8040 Sales YoY Growth (2021-2032) & (K Units) Figure 13. Binimetinib Image Figure 14. Global Binimetinib Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Type 2025 VS 2032 Figure 19. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Relapsed Acute Myeloid Leukemia Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Application 2025 VS 2032 Figure 39. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Relapsed Acute Myeloid Leukemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Relapsed Acute Myeloid Leukemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Relapsed Acute Myeloid Leukemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Relapsed Acute Myeloid Leukemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Relapsed Acute Myeloid Leukemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Relapsed Acute Myeloid Leukemia Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Relapsed Acute Myeloid Leukemia Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • aNK Program
  • AT-9283
  • BI-836858
  • BL-8040
  • Binimetinib
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • 4SC AG
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • CTI BioPharma Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Boehringer Ingelheim GmbH
  • BioLineRx, Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Astex Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Array BioPharma Inc.
  • Arog Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Relapsed Acute Myeloid Leukemia Drug Market by Type
  6. 1.3.1 aNK Program
  7. 1.3.2 AT-9283
  8. 1.3.3 BI-836858
  9. 1.3.4 BL-8040
  10. 1.3.5 Binimetinib
  11. 1.3.6 Others
  12. 1.4 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Type
  13. 1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
  2. 2.2 Relapsed Acute Myeloid Leukemia Drug Industry Drivers
  3. 2.3 Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges
  4. 2.4 Relapsed Acute Myeloid Leukemia Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Relapsed Acute Myeloid Leukemia Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Relapsed Acute Myeloid Leukemia Drug Price (2021-2026)
  4. 3.4 Global Relapsed Acute Myeloid Leukemia Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Relapsed Acute Myeloid Leukemia Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Relapsed Acute Myeloid Leukemia Drug Company, Product Type & Application
  7. 3.7 Global Relapsed Acute Myeloid Leukemia Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Relapsed Acute Myeloid Leukemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Relapsed Acute Myeloid Leukemia Drug Tier 1, Tier 2, and Tier 3
4 Relapsed Acute Myeloid Leukemia Drug Regional Status and Outlook
  1. 4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Size by Region
  3. 4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Market Size by Region
  7. 4.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Relapsed Acute Myeloid Leukemia Drug by Application
  1. 5.1 Relapsed Acute Myeloid Leukemia Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Application
  6. 5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 4SC AG
  2. 6.1.1 4SC AG Company Information
  3. 6.1.2 4SC AG Business Overview
  4. 6.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  6. 6.1.5 4SC AG Recent Developments
  7. 6.2 Amgen Inc.
  8. 6.2.1 Amgen Inc. Company Information
  9. 6.2.2 Amgen Inc. Business Overview
  10. 6.2.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  12. 6.2.5 Amgen Inc. Recent Developments
  13. 6.3 AbbVie Inc.
  14. 6.3.1 AbbVie Inc. Company Information
  15. 6.3.2 AbbVie Inc. Business Overview
  16. 6.3.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  18. 6.3.5 AbbVie Inc. Recent Developments
  19. 6.4 AstraZeneca Plc
  20. 6.4.1 AstraZeneca Plc Company Information
  21. 6.4.2 AstraZeneca Plc Business Overview
  22. 6.4.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  24. 6.4.5 AstraZeneca Plc Recent Developments
  25. 6.5 CTI BioPharma Corp.
  26. 6.5.1 CTI BioPharma Corp. Company Information
  27. 6.5.2 CTI BioPharma Corp. Business Overview
  28. 6.5.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  30. 6.5.5 CTI BioPharma Corp. Recent Developments
  31. 6.6 Cornerstone Pharmaceuticals, Inc.
  32. 6.6.1 Cornerstone Pharmaceuticals, Inc. Company Information
  33. 6.6.2 Cornerstone Pharmaceuticals, Inc. Business Overview
  34. 6.6.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  36. 6.6.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
  37. 6.7 Celgene Corporation
  38. 6.7.1 Celgene Corporation Company Information
  39. 6.7.2 Celgene Corporation Business Overview
  40. 6.7.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  42. 6.7.5 Celgene Corporation Recent Developments
  43. 6.8 Calithera Biosciences, Inc.
  44. 6.8.1 Calithera Biosciences, Inc. Company Information
  45. 6.8.2 Calithera Biosciences, Inc. Business Overview
  46. 6.8.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  48. 6.8.5 Calithera Biosciences, Inc. Recent Developments
  49. 6.9 Bristol-Myers Squibb Company
  50. 6.9.1 Bristol-Myers Squibb Company Company Information
  51. 6.9.2 Bristol-Myers Squibb Company Business Overview
  52. 6.9.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 6.10 Boston Biomedical, Inc.
  56. 6.10.1 Boston Biomedical, Inc. Company Information
  57. 6.10.2 Boston Biomedical, Inc. Business Overview
  58. 6.10.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  60. 6.10.5 Boston Biomedical, Inc. Recent Developments
  61. 6.11 Boehringer Ingelheim GmbH
  62. 6.11.1 Boehringer Ingelheim GmbH Company Information
  63. 6.11.2 Boehringer Ingelheim GmbH Business Overview
  64. 6.11.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  66. 6.11.5 Boehringer Ingelheim GmbH Recent Developments
  67. 6.12 BioLineRx, Ltd.
  68. 6.12.1 BioLineRx, Ltd. Company Information
  69. 6.12.2 BioLineRx, Ltd. Business Overview
  70. 6.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  72. 6.12.5 BioLineRx, Ltd. Recent Developments
  73. 6.13 AVEO Pharmaceuticals, Inc.
  74. 6.13.1 AVEO Pharmaceuticals, Inc. Company Information
  75. 6.13.2 AVEO Pharmaceuticals, Inc. Business Overview
  76. 6.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  78. 6.13.5 AVEO Pharmaceuticals, Inc. Recent Developments
  79. 6.14 Astex Pharmaceuticals, Inc.
  80. 6.14.1 Astex Pharmaceuticals, Inc. Company Information
  81. 6.14.2 Astex Pharmaceuticals, Inc. Business Overview
  82. 6.14.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  84. 6.14.5 Astex Pharmaceuticals, Inc. Recent Developments
  85. 6.15 Astellas Pharma Inc.
  86. 6.15.1 Astellas Pharma Inc. Company Information
  87. 6.15.2 Astellas Pharma Inc. Business Overview
  88. 6.15.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  90. 6.15.5 Astellas Pharma Inc. Recent Developments
  91. 6.16 Array BioPharma Inc.
  92. 6.16.1 Array BioPharma Inc. Company Information
  93. 6.16.2 Array BioPharma Inc. Business Overview
  94. 6.16.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  96. 6.16.5 Array BioPharma Inc. Recent Developments
  97. 6.17 Arog Pharmaceuticals, Inc.
  98. 6.17.1 Arog Pharmaceuticals, Inc. Company Information
  99. 6.17.2 Arog Pharmaceuticals, Inc. Business Overview
  100. 6.17.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  102. 6.17.5 Arog Pharmaceuticals, Inc. Recent Developments
  103. 6.18 Agios Pharmaceuticals, Inc.
  104. 6.18.1 Agios Pharmaceuticals, Inc. Company Information
  105. 6.18.2 Agios Pharmaceuticals, Inc. Business Overview
  106. 6.18.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  108. 6.18.5 Agios Pharmaceuticals, Inc. Recent Developments
  109. 6.19 Actinium Pharmaceuticals, Inc.
  110. 6.19.1 Actinium Pharmaceuticals, Inc. Company Information
  111. 6.19.2 Actinium Pharmaceuticals, Inc. Business Overview
  112. 6.19.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  114. 6.19.5 Actinium Pharmaceuticals, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country
  2. 7.1.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  6. 7.2.1 North America Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country
  2. 8.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  6. 8.2.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country
  2. 9.1.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Relapsed Acute Myeloid Leukemia Drug Sales by Country
  2. 10.1.1 South America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  6. 10.2.1 South America Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country
  2. 11.1.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
  2. 12.1.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
  7. 12.2 Relapsed Acute Myeloid Leukemia Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Relapsed Acute Myeloid Leukemia Drug Distributors
  10. 12.2.3 Relapsed Acute Myeloid Leukemia Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst